[
    [
        {
            "time": "2023-10-05",
            "original_text": "Pharma ETFs Soar on Robust Q2 Earnings",
            "features": {
                "keywords": [
                    "Pharma",
                    "ETFs",
                    "Soar",
                    "Robust",
                    "Q2",
                    "Earnings"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma ETFs Soar on Robust Q2 Earnings",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Roundup",
                    "ABBV",
                    "MRK",
                    "Q2",
                    "Earnings",
                    "Coronavirus",
                    "Updates"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Highlights",
                    "Apple",
                    "Mastercard",
                    "Eli Lilly",
                    "PetroChina",
                    "Anheuser-Busch InBev"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "financial services",
                    "pharmaceuticals",
                    "energy",
                    "consumer goods"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment",
            "features": {
                "keywords": [
                    "NIH",
                    "test",
                    "remdesivir",
                    "Merck KGaA",
                    "interferon",
                    "therapy",
                    "COVID-19",
                    "treatment"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]